News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Yesafili, received marketing authorization approval from the European Commission for the European Union
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Subscribe To Our Newsletter & Stay Updated
